Frank Palantoni joins Laboratoire M2 as CEO
June 22 2016 - 10:00AM
Laboratoire M2, (LabM2) the company behind THYMOX™, the new
standard in environmentally sustainable disinfecting technologies,
is proud to announce that Frank Palantoni, a seasoned global
executive, has joined the company as CEO.
A photo accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/e33a443f-0747-4eab-965b-6b3d59333979
“I’m excited to work with Serge Auray, President
and Founder, and the entire LabM2 team, at this important growth
stage as our company transitions from a research and development
platform, to executing a strategy of rapid commercial development
of THYMOX™’s breakthrough technology in North America, Europe and
Asia,” said Palantoni, who will be based in San Francisco.
THYMOX™’s disruptive and environmentally friendly
antimicrobial technology is botanically derived to harnesses the
power of nature’s own antimicrobial properties to tackle some of
nature’s most difficult pathogenic problems. Commercial use
of THYMOX™ in agriculture and animal health has already saved the
environment from poisoning by tons of heavy metals that would
otherwise have been washed into the soil. The continued commercial
expansion of THYMOX™ has the potential to eliminate the use of
millions of pounds of copper sulfate in the dairy industry each
year. In other sectors, including institutional and home
environments, THYMOX™ products have eliminated chemicals which are
otherwise environmentally damaging, and hazardous to humans.
Prior to being named CEO, Mr. Palantoni joined
LabM2 as a strategic advisor in June 2015. Previously, Mr.
Palantoni was President of Pet and Life Science Divisions at
Central Garden & Pet (NASDAQ:CENTA) a leading animal health
products company. During his 30 year career, Mr. Palantoni has
served as Global CEO of Gerber Products, and CEO of Novartis
Consumer Health, NA. Earlier, he was amongst the top executives at
Groupe Danone, and held senior positions at Kraft and Procter &
Gamble.
Mr. Palantoni is currently also a Director of
Lexicon Pharmaceuticals (NASDAQ:LXRX), a biopharmaceutical company
engaged in discovering and developing breakthrough treatments for
human diseases such as cancer and diabetes. He holds a B.S. from
Tufts University, and an MBA from Columbia University.
“We are pleased to have Frank Palantoni as the new
CEO of LabM2 as we continue to grow. He has already had a great
impact within our team since his arrival last June. His leadership
and experience will continue to be very positive for the company,
especially with the exciting opportunities we face,” says Mario
Allaire, Chairman of the Board of Directors of LabM2.
International Expansion
Accelerates
One of Mr. Palantoni’s main objectives will be the
continued international commercial expansion of THYMOX™.
Fuelled by a round of investment, led by Canada’s leading
cooperative financial group, Desjardins Innovatech ($200 billion in
assets), which closed in 3rd quarter of 2015, LabM2 made
significant commercial inroads into the Chinese and European animal
health markets in the 1st quarter of 2016. Cycle Capital
Management, the most active Canadian cleantech venture capital
platform, which made its first LabM2 investment in 2012, also
participated in last year’s round. In the second half of 2016,
LabM2 will be focussing more of its attention on the North American
animal health market, as well as boosting its efforts in crop and
consumer sectors.
About Laboratoire
M2
Laboratoire M2, based in Sherbrooke, Canada, has
built a well-respected reputation for product innovation and
expertise in environmentally sustainable “green” disinfection and
bio-security technology under the trademark THYMOX™. The company
currently markets a range of leading biodegradable, disinfecting
and anti-microbial products based on their proprietary technology
platform, which are environmentally certified by UL (Ecologo2794).
In addition, Laboratoire M2 biodegradable animal health products
are effective against the bacteria and fungus known to be the cause
of damaging and costly bovine hoof infections (digital dermatitis)
in the dairy industry. The company also distributes products and
ingredients under private label agreements in institutional and
retail markets, as well as in the crop protection market. For more
information about Laboratoire M2 visit thymox.com
Contact: Mathieu Lavallée (Canada)
mlavallee@cyclecapital.com /514-947-7628
Contact: Marcia Clark (U.S.)
mc@contentmachinellc.com/914-523-9314
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024